Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib and Osimertinib in EGFR-mutated NSCLC
NCT02917993Phase 2Completed
- Sponsor
- Incyte
- Start
- Dec 2016
- Primary completion
- Dec 2025
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in non-small cell lung cancer (NSCLC), sponsored by Incyte. Primary endpoints: Adverse Events at 2 years, Dose-Limiting Toxicities at 28 days and 1 more. Started Dec 2016; status: completed.
02
Drugs
itacitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02917993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917993.